These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38170550)

  • 1. New approaches for human epidermal growth factor receptor 2-low and human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
    Britten K; McAndrew N
    Curr Opin Obstet Gynecol; 2024 Feb; 36(1):34-39. PubMed ID: 38170550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
    Modi S; Jacot W; Yamashita T; Sohn J; Vidal M; Tokunaga E; Tsurutani J; Ueno NT; Prat A; Chae YS; Lee KS; Niikura N; Park YH; Xu B; Wang X; Gil-Gil M; Li W; Pierga JY; Im SA; Moore HCF; Rugo HS; Yerushalmi R; Zagouri F; Gombos A; Kim SB; Liu Q; Luo T; Saura C; Schmid P; Sun T; Gambhire D; Yung L; Wang Y; Singh J; Vitazka P; Meinhardt G; Harbeck N; Cameron DA;
    N Engl J Med; 2022 Jul; 387(1):9-20. PubMed ID: 35665782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.
    Niikura N; Liu J; Hayashi N; Mittendorf EA; Gong Y; Palla SL; Tokuda Y; Gonzalez-Angulo AM; Hortobagyi GN; Ueno NT
    J Clin Oncol; 2012 Feb; 30(6):593-9. PubMed ID: 22124109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.
    Gradishar WJ
    Ann Oncol; 2013 Oct; 24(10):2492-2500. PubMed ID: 23827380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
    Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
    Kim JW; Kim JH; Im SA; Lee KH; Kim JS; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1023-9. PubMed ID: 24036907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2-positive metastatic breast cancer: trastuzumab and beyond.
    Metro G; Mottolese M; Fabi A
    Expert Opin Pharmacother; 2008 Oct; 9(15):2583-601. PubMed ID: 18803447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
    Chung C; Lam MS
    Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
    Tesch ME; Gelmon KA
    Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.
    Smyth LM; Iyengar NM; Chen MF; Popper SM; Patil S; Wasserheit-Lieblich C; Argolo DF; Singh JC; Chandarlapaty S; Sugarman SM; Comen EA; Drullinsky PR; Traina TA; Troso-Sandoval T; Baselga J; Norton L; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2016 Jul; 158(1):91-97. PubMed ID: 27306421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021.
    McAndrew NP
    Curr Opin Obstet Gynecol; 2022 Feb; 34(1):41-45. PubMed ID: 34967814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
    De Mattos-Arruda L; Cortes J
    Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
    Dempsey N; Sandoval A; Mahtani R
    Curr Treat Options Oncol; 2023 Sep; 24(9):1120-1137. PubMed ID: 37428332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.
    Nie T; Blair HA
    Target Oncol; 2023 May; 18(3):463-470. PubMed ID: 37129796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer.
    Tsang RY; Finn RS
    Br J Cancer; 2012 Jan; 106(1):6-13. PubMed ID: 22215104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
    Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S
    Trials; 2020 May; 21(1):391. PubMed ID: 32381018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
    Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
    Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-positive metastatic breast cancer: a comprehensive review.
    Exman P; Tolaney SM
    Clin Adv Hematol Oncol; 2021 Jan; 19(1):40-50. PubMed ID: 33493147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.